Cingulate Inc. Depreciation
Cingulate Inc. (CING) reported Depreciation of $98.24 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-13
- Cingulate Inc. depreciation for the quarter ending 2026-06-30 was $98.24K, a 33.16% decline year-over-year.
- Cingulate Inc. depreciation for the quarter ending 2026-03-31 was $121.19K, a 26.68% decline year-over-year.
- Cingulate Inc. depreciation for the quarter ending 2025-12-31 was $121.83K, a 24.00% decline year-over-year.
- Cingulate Inc. depreciation for the quarter ending 2025-09-30 was $106.78K, a 35.44% decline year-over-year.
- Cingulate Inc. depreciation for fiscal 2025 was $540.89K, a 17.18% decline from fiscal 2024.
- Cingulate Inc. depreciation for fiscal 2024 was $653.09K, a 12.04% increase from fiscal 2023.
- Cingulate Inc. depreciation for fiscal 2023 was $582.92K, a 47.94% increase from fiscal 2022.
- Cingulate Inc. depreciation for fiscal 2022 was $394.01K, a 44.37% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $98.24K 10-Q · filed 2026-08-13 | $219.43K 10-Q · filed 2026-08-13 | $341.26K derived: sum of 3 quarters · filed 2026-08-13 | $448.04K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $121.19K 10-Q · filed 2026-05-14 | $243.02K derived: sum of 2 quarters · filed 2026-05-14 | $349.80K derived: sum of 3 quarters · filed 2026-05-14 | $496.79K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $121.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $228.61K derived: sum of 2 quarters · filed 2026-03-18 | $375.60K derived: sum of 3 quarters · filed 2026-08-13 | $540.89K 10-K · filed 2026-03-18 |
| 2025-09-30 | $106.78K 10-Q · filed 2025-11-13 | $253.77K derived: sum of 2 quarters · filed 2026-08-13 | $419.06K 10-Q · filed 2025-11-13 | $579.36K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $146.99K 10-Q · filed 2026-08-13 | $312.28K 10-Q · filed 2026-08-13 | $472.58K derived: sum of 3 quarters · filed 2026-08-13 | $637.99K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $165.29K 10-Q · filed 2026-05-14 | $325.59K derived: sum of 2 quarters · filed 2026-05-14 | $491.00K derived: sum of 3 quarters · filed 2026-05-14 | $654.78K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $160.30K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $325.71K derived: sum of 2 quarters · filed 2026-03-18 | $489.49K derived: sum of 3 quarters · filed 2026-03-18 | $653.09K 10-K · filed 2026-03-18 |
| 2024-09-30 | $165.41K 10-Q · filed 2025-11-13 | $329.19K derived: sum of 2 quarters · filed 2025-11-13 | $492.79K 10-Q · filed 2025-11-13 | $665.11K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $163.78K 10-Q · filed 2025-08-19 | $327.38K 10-Q · filed 2025-08-19 | $499.71K derived: sum of 3 quarters · filed 2025-08-19 | $654.37K derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | $163.60K 10-Q · filed 2025-05-08 | $335.93K derived: sum of 2 quarters · filed 2025-05-08 | $490.59K derived: sum of 3 quarters · filed 2025-05-08 | $645.89K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $172.32K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $326.99K derived: sum of 2 quarters · filed 2025-03-27 | $482.29K derived: sum of 3 quarters · filed 2025-03-27 | $582.92K 10-K · filed 2025-03-27 |
| 2023-09-30 | $154.66K 10-Q · filed 2024-11-07 | $309.96K derived: sum of 2 quarters · filed 2024-11-07 | $410.59K 10-Q · filed 2024-11-07 | $500.32K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $155.30K 10-Q · filed 2024-08-13 | $255.93K 10-Q · filed 2024-08-13 | $345.65K derived: sum of 3 quarters · filed 2024-08-13 | $447.08K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $100.63K 10-Q · filed 2024-05-08 | $190.35K derived: sum of 2 quarters · filed 2024-05-08 | $291.78K derived: sum of 3 quarters · filed 2024-05-08 | $393.21K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $89.72K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $191.15K derived: sum of 2 quarters · filed 2024-04-01 | $292.58K derived: sum of 3 quarters · filed 2024-04-01 | $394.01K 10-K · filed 2024-04-01 |
| 2022-09-30 | $101.43K 10-Q · filed 2023-11-13 | $202.86K derived: sum of 2 quarters · filed 2023-11-13 | $304.29K 10-Q · filed 2023-11-13 | $483.80K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $101.43K 10-Q · filed 2023-08-14 | $202.86K 10-Q · filed 2023-08-14 | $382.37K derived: sum of 3 quarters · filed 2023-08-14 | $460.16K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $101.43K 10-Q · filed 2023-05-10 | $280.94K derived: sum of 2 quarters · filed 2023-05-10 | $358.73K derived: sum of 3 quarters · filed 2023-05-10 | $435.59K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $179.51K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $257.31K derived: sum of 2 quarters · filed 2023-03-10 | $334.16K derived: sum of 3 quarters · filed 2023-03-10 | $708.32K 10-K · filed 2023-03-10 |
| 2021-09-30 | $77.80K 10-Q · filed 2022-11-14 | $154.65K derived: sum of 2 quarters · filed 2022-11-14 | $528.81K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $76.85K 10-Q · filed 2022-08-11 | $351.29K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $174.70K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $666.03K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |